⌘K
t
Oxford Nanopore Technologies plc held its Annual General Meeting on 04 June 2025, where all 21 resolutions, as set out in the Notice dated 30 April 2025, were passed by shareholders on a poll. These resolutions included the election of Dr Daniel Mahony, re-election of other directors, approval of company reports, and the appointment of Deloitte LLP as auditors. A total of 960,995,120 ordinary shares were eligible to be voted, with Resolution 12, regarding the re-election of Duncan Tatton-Brown, receiving 219,531,387 votes (34.17%) against.
| Date | 4 Jun 2025 |
| Time | 13:00:00 |
| Category | AGMs and other meetings |
| ID | 4368L |
04 June 2025
Oxford Nanopore Technologies plc
(the "Company")
Results of Annual General Meeting
The Annual General Meeting of the Company was held earlier today. All resolutions, as set out in the Company's Notice of Annual General Meeting dated 30 April 2025, were passed by the appropriate majority on a poll. Details of the poll results are set out below.
Oxford Nanopore Technologies plc Annual General Meeting Poll Results:
|
No. |
RESOLUTION |
VOTES |
% |
VOTES |
% |
VOTES |
% of ISC VOTED |
VOTES |
|
1. |
To receive and consider the Directors' report, the Audited Statement of Accounts and Auditor's Report of the Company for the financial year ended 31 December 2024 |
642,469,240 |
100.00 |
25,908 |
0.00 |
642,495,148 |
66.86% |
6,876,840 |
|
2. |
To receive and approve the Directors' Remuneration Report for the year ended 31 December 2024 |
640,466,861 |
99.66 |
2,175,681 |
0.34 |
642,642,542 |
66.87% |
6,729,446 |
|
3. |
To receive and approve the Directors' Remuneration Policy |
640,487,359 |
99.58 |
2,691,923 |
0.42 |
643,179,282 |
66.93% |
6,192,706 |
|
4. |
To elect Dr Daniel Mahony as a director of the Company |
636,940,143 |
99.98 |
118,587 |
0.02 |
637,058,730 |
66.29% |
12,313,258 |
|
5. |
To re-elect Dr Sarah Fortune as a director of the Company |
633,477,558 |
98.52 |
9,519,311 |
1.48 |
642,996,869 |
66.91% |
6,375,119 |
|
6. |
To re-elect Adrian Hennah as a director of the Company |
630,186,574 |
98.01 |
12,805,716 |
1.99 |
642,992,290 |
66.91% |
6,379,698 |
|
7. |
To re-elect Nicholas Keher as a director of the Company |
637,060,716 |
99.98 |
141,931 |
0.02 |
637,202,647 |
66.31% |
12,169,341 |
|
8. |
To re-elect John O'Higgins as a director of the Company |
637,006,927 |
99.08 |
5,932,235 |
0.92 |
642,939,162 |
66.90% |
6,432,826 |
|
9. |
To re-elect Dr Heather Preston as a director of the Company |
633,553,236 |
98.52 |
9,521,168 |
1.48 |
643,074,404 |
66.92% |
6,297,584 |
|
10. |
To re-elect Katherine (Kate) Priestman as a director of the Company |
630,088,976 |
97.98 |
12,990,968 |
2.02 |
643,079,944 |
66.92% |
6,292,044 |
|
11. |
To re-elect Dr Gurdial (Gordon) Sanghera as a director of the Company |
636,100,503 |
98.90 |
7,082,497 |
1.10 |
643,183,000 |
66.93% |
6,188,988 |
|
12. |
To re-elect Duncan Tatton-Brown as a director of the Company |
423,014,842 |
65.83 |
219,531,387 |
34.17 |
642,546,229 |
66.86% |
6,825,759 |
|
13. |
To appoint Deloitte LLP as auditors of the Company |
638,373,565 |
99.25 |
4,818,777 |
0.75 |
643,192,342 |
66.93% |
6,179,646 |
|
14. |
To authorise the Audit & Risk Committee to determine the remuneration of the auditors |
643,005,482 |
99.97 |
195,114 |
0.03 |
643,200,596 |
66.93% |
6,171,392 |
|
15. |
To authorise the board of directors to allot shares |
636,523,885 |
98.96 |
6,672,536 |
1.04 |
643,196,421 |
66.93% |
6,175,567 |
|
16. |
To disapply pre-emption rights* |
638,525,364 |
99.30 |
4,490,000 |
0.70 |
643,015,364 |
66.91% |
6,356,624 |
|
17. |
To further disapply pre-emption rights* |
630,426,434 |
98.04 |
12,581,864 |
1.96 |
643,008,298 |
66.91% |
6,363,690 |
|
18. |
To authorise the Company to make market purchases* |
643,119,265 |
99.98 |
113,576 |
0.02 |
643,232,841 |
66.93% |
6,139,147 |
|
19. |
To authorise the Company to hold any general meeting (other than an Annual General Meeting) on not less than 14 clear days' notice* |
641,615,906 |
99.75 |
1,619,955 |
0.25 |
643,235,861 |
66.93% |
6,136,127 |
|
20. |
To authorise UK political expenditure not exceeding £100,000 |
642,333,582 |
99.90 |
660,073 |
0.10 |
642,993,655 |
66.91% |
6,378,333 |
|
21. |
To authorise the proposed amendment to the LTIP rules |
641,683,377 |
99.80 |
1,285,980 |
0.20 |
642,969,357 |
66.91% |
6,402,631 |
* Special Resolution
NOTES:
1. Votes "For" and "Against" are expressed as a percentage of votes received.
2. The total number of ordinary shares in issue and eligible to be voted on at the AGM was 960,995,120.
3. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution nor in the calculation of the proportion of "Total issued share capital voted" for any resolution.
4. The Board appreciates the support shown by shareholders for the resolutions at today's AGM. Whilst all resolutions were passed, the Board acknowledges the outcome of the vote on Resolution 12, for which over 20% of votes cast were against. The Board will continue to engage with shareholders in constructive and open dialogue around the reasons for the votes against this Resolution and will provide an update to shareholders within six months of today's meeting.
In accordance with Listing Rule 9.6.2, a copy of the resolutions will shortly be submitted to the National Storage Mechanism and will be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
A copy of the poll results for the AGM will also be available shortly on the Company's website at https://nanoporetech.com/about-us/investors/shareholder-information.
-ENDS-
For further information please contact:
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used in more than 125 countries to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. For more information, please visit: https://nanoporetech.com/